• Buspiron -Anksiolitik
• Dasatinib - Lek protiv kancera
• Eptapiron - Anksiolitik
• Gepiron - Anksiolitik
• Ipsapiron - Anksiolitik
• Piribedil - Antiparkinsonski agens
• Revospiron - Anksiolitik
• Tandospiron - Anksiolitik
• Tirilazad - Alfa blokator
• Umespiron - Anksiolitik
• Zalospiron - Anksiolitik

Reference

1. ^Li Q, Cheng T, Wang Y, Bryant SH (2010).„PubChem as a public resource for drug discovery.”.Drug Discov Today.15 (23-24): 1052—7.PMID 20970519.doi:10.1016/j.drudis.2010.10.003.  уреди
2. ^Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”.Annual Reports in Computational Chemistry.4: 217—241.doi:10.1016/S1574-1400(08)00012-1. 
3. ^^абBlier; Curet, O.; Chaput, Y.; De Montigny, C. (1991).„Tandospirone and its metabolite, 1-(2-pyrimidinyl)-piperazine--II. Effects of acute administration of 1-PP and long-term administration of tandospirone on noradrenergic neurotransmission”.Neuropharmacology.30 (7): 691—701.PMID 1681447.doi:10.1016/0028-3908(91)90176-C. 
4. ^Zuideveld, K. P.; Rusic-pavletic, J.; Maas, H. J.; Peletier, L. A.; Van Der Graaf, P. H. & Danhof, M. (2002). „Pharmacokinetic-pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in rats”.The Journal of Pharmacology and Experimental Therapeutics.303 (3): 1130—1137.PMID 12438536.doi:10.1124/jpet.102.036798. 
5. ^Astier; Lambás Señas, L.; Soulière, F.; Schmitt, P.; Urbain, N.; Rentero, N.; Bert, L.; Denoroy, L.; et al. (2003). „In vivo comparison of two 5-HT1A receptors agonists alnespirone (S-20499) and buspirone on locus coeruleus neuronal activity”.European Journal of Pharmacology.459 (1): 17—26.PMID 12505530.doi:10.1016/S0014-2999(02)02814-5. 

Spoljašnje veze